Patents by Inventor Carina Vingsbo-Lundberg
Carina Vingsbo-Lundberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10519202Abstract: The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis, M. bovis, M. africanum), The invention is based on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.Type: GrantFiled: December 12, 2014Date of Patent: December 31, 2019Assignee: STATENS SERUM INSTITUTInventors: Jes Dietrich, Peter Andersen, Carina Vingsbo Lundberg, Truc Thi Kim Than Hoang
-
Patent number: 9074001Abstract: The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis, M. bovis, M. africanum). The invention is base on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.Type: GrantFiled: April 23, 2010Date of Patent: July 7, 2015Assignee: STATENS SERUM INSTITUTInventors: Jes Dietrich, Peter Andersen, Carina Vingsbo Lundberg, Truc Thi Kim Than Hoang
-
Publication number: 20150093407Abstract: The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis., M. bovis, M. africanum), The invention is based on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.Type: ApplicationFiled: December 12, 2014Publication date: April 2, 2015Inventors: Jes Dietrich, Peter Andersen, Carina Vingsbo Lundberg, Truc Thi Kim Than Hoang
-
Patent number: 8703151Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: GrantFiled: September 20, 2012Date of Patent: April 22, 2014Assignee: Statens Serum InstitutInventors: Claus Aagaard, Carina Vingsbo-Lundberg, Peter Anderson
-
Patent number: 8293250Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: GrantFiled: December 22, 2011Date of Patent: October 23, 2012Assignee: Statens Serum InstitutInventors: Claus Aagaard, Carina Vingsbo-Lundberg, Peter Andersen
-
Publication number: 20120114687Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: ApplicationFiled: December 22, 2011Publication date: May 10, 2012Applicant: STATENS SERUM INSTITUTInventors: Claus Aagard, Carina Vingsbo-Lundberg, Peter Andersen
-
Publication number: 20120039925Abstract: The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis, M. bovis, M. africanum). The invention is base on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.Type: ApplicationFiled: April 23, 2010Publication date: February 16, 2012Applicant: STATENS SERUM INSTITUTInventors: Jes Dietrich, Peter Andersen, Carina Vingsbo Lundberg, Truc Thi Kim Than Hoang
-
Patent number: 8101193Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: GrantFiled: May 5, 2011Date of Patent: January 24, 2012Assignee: Statens Serum InstitutInventors: Claus Aagaard, Carina Vingsbo-Lundberg, Peter Andersen
-
Publication number: 20110206713Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: ApplicationFiled: May 5, 2011Publication date: August 25, 2011Applicant: STATENS SERUM INSTITUTInventors: Claus Aagard, Carina Vingsbo-Lundberg, Peter Andersen
-
Patent number: 7968105Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: GrantFiled: June 20, 2006Date of Patent: June 28, 2011Assignee: Statens Serum InstitutInventors: Claus Aagaard, Carina Vingsbo-Lundberg, Peter Andersen
-
Publication number: 20090186048Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: ApplicationFiled: June 20, 2006Publication date: July 23, 2009Applicant: Statens Serum InstitutInventors: Claus Aagaard, Carina Vingsbo-Lundberg, Peter Andersen